ArticlebioRxiv : the preprint server for biology2025
Optimizing cardiac organoid culture to enhance maturation, viability, and cardiotoxicity assessments.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Development of relevant, human induced pluripotent stem cell-derived cardiac organoids is essential to recapitulate myocardium physiology and functionality for assessment of drug-induced toxicity evaluations. However, the optimal conditions for culturing self-aggregating multicellular cardiac organoids are not well-elucidated, particularly the impact of noncardiomyocytes. In this study, we generated cardiac organoids at varying seeding densities to formulate organoids that meet or exceed the biological diffusion limit. We assessed their morphology, gene expression profiles, beating functionality, viability, and mitochondrial activity over time. Our results show that organoid sizes stabilize by seven days of culture, regardless of seeding density. However, organoids seeded with 20,000 cells retained an optimal cardiac signature that promotes cardiac maturity and minimizes fibrotic tendencies, especially when culturing longer than seven days. While all organoid populations maintained their beating functionalities, those seeded with 80,000 cells exhibited greater cell shedding and increased apoptosis at long term culture. In contrast, minimal apoptosis was observed in organoids seeded with 20,000 cells after seven days. Mitochondrial staining further revealed that organoids seeded with 20,000 cells consistently demonstrated higher metabolic activity. Taken together, organoids seeded with 20,000 cells and cultured for seven days yielded the healthiest morphology, transcriptional signature, and viability, while maintaining robust beating kinetics. Importantly, compared to 2D cultures, these optimized organoids demonstrate improved sensitivity to clinically relevant doxorubicin-induced cardiotoxicity, enabling more accurate dose-response evaluations that better reflect therapeutic conditions. Impact Statement: This work highlights key tissue engineering considerations for generating self-assembling cardiac organoids suitable for scalable, high-throughput drug screening and discovery. Understanding the effect of seeding density and culture duration on organoid size and, consequently on gene expression, beating functionalities, apoptosis, and metabolic activity, has broader implications for establishing optimal organoid culture conditions. These insights enable the production of large quantities of cardiac organoids capable of modeling drug-induced toxicity effects on a clinically relevant timescale.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.